Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study.

Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, Katsanos A, Oddone F, Torri V, Weinreb RN; Italian Study Group on QoL in Glaucoma.

Sci Rep. 2018 Jan 12;8(1):619. doi: 10.1038/s41598-017-19113-z.

2.

The prognostic role of tumor size in early breast cancer in the era of molecular biology.

Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, Cordovana A, Farina G, Bramati A, Piva S, Dazzani MC, Paternò E, La Verde NM.

PLoS One. 2017 Dec 6;12(12):e0189127. doi: 10.1371/journal.pone.0189127. eCollection 2017.

3.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

4.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.

ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. Review.

5.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

6.

Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics.

Quaranta L, Biagioli E, Galli F, Poli D, Rulli E, Riva I, Hollander L, Katsanos A, Longo A, Uva MG, Torri V, Weinreb RN.

Adv Ther. 2016 Aug;33(8):1305-15. doi: 10.1007/s12325-016-0358-x. Epub 2016 Jun 16.

7.

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.

Faloppi L, Bianconi M, Giampieri R, Sobrero A, Labianca R, Ferrari D, Barni S, Aitini E, Zaniboni A, Boni C, Caprioni F, Mosconi S, Fanello S, Berardi R, Bittoni A, Andrikou K, Cinquini M, Torri V, Scartozzi M, Cascinu S; Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Oncotarget. 2015 Oct 27;6(33):35087-94. doi: 10.18632/oncotarget.5197.

8.

DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected].

Polato F, Rusconi P, Zangrossi S, Morelli F, Boeri M, Musi A, Marchini S, Castiglioni V, Scanziani E, Torri V, Broggini M.

J Natl Cancer Inst. 2014 Apr;106(4):dju053. doi: 10.1093/jnci/dju053. Epub 2014 Mar 20. Erratum in: J Natl Cancer Inst. 2014 Aug;106(8):dju199 doi:10.1093/jnci/dju199.

9.

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study.

Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P.

Int J Breast Cancer. 2014;2014:769790. doi: 10.1155/2014/769790. Epub 2014 Jan 16.

10.

ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G.

Am J Cancer Res. 2013 Apr 3;3(2):221-9. Print 2013.

11.

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G.

PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5.

12.

The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis.

Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA, Gordon MO.

BMC Med Res Methodol. 2012 Oct 4;12:151. doi: 10.1186/1471-2288-12-151.

13.

Evidence-based guidelines: Improving AGREEment on consistence evaluation.

Vincenzi B, Napolitano A, Santini D, Maiello E, Torri V, Tonini G.

J Bone Oncol. 2012 Apr 30;1(1):30-4. doi: 10.1016/j.jbo.2012.04.001. eCollection 2012 Jun.

14.

Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S.

PLoS One. 2012;7(5):e36411. doi: 10.1371/journal.pone.0036411. Epub 2012 May 4.

16.

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, Cappuzzo F, Vander Borght S, Martin V, Skokan M, Santoro A, Gambacorta M, Tejpar S, Varella-Garcia M, Siena S.

J Clin Pathol. 2012 Mar;65(3):218-23. doi: 10.1136/jclinpath-2011-200353. Epub 2011 Nov 30. Erratum in: J Clin Pathol. 2012 Jul;65(7):674.

17.

Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells.

Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, Mantovani S, Marinou K, Papetti L, Monteforte M, Torri V, Paris L, Bazzoni G, Lunetta C, Corbo M, Mora G, Bendotti C, Bonetto V.

PLoS One. 2011;6(10):e25545. doi: 10.1371/journal.pone.0025545. Epub 2011 Oct 5.

18.

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.

J Clin Oncol. 2010 Jul 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.

19.

Do we need biopsies of metastases for colorectal cancer patients?

Floriani I, Santini D, Torri V, Cremolini C, Falcone A, Loupakis F.

Br J Cancer. 2009 Jul 21;101(2):374-5; author reply 376. doi: 10.1038/sj.bjc.6605131. Epub 2009 Jul 7. No abstract available.

20.

Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials.

Floriani I, Rotmensz N, Albertazzi E, Torri V, De Rosa M, Tomino C, de Braud F.

Trials. 2008 Jul 25;9:46. doi: 10.1186/1745-6215-9-46.

Supplemental Content

Loading ...
Support Center